陆小云，女，博士，研究员，博士生导师，国家优秀青年基金获得者，863青年科学家，广东省****基金获得者和广东省特支计划青年拔尖人才。近年来重点围绕肺结核和肺癌等重要肺部疾病的临床需求，针对疾病密切相关的生物学靶标，利用“基于结构的药物设计”为技术手段，设计和合成全新的药物先导物，为治疗肺部疾病的创新药物研发提供化学物质基础。以第一或通讯作者在Angew. Chem. Int. Edit.和J. Med. Chem.等本专业期刊发表SCI论文50余篇。参编英文专著2部。申请发明专利30余项，授权12项（美国1项），部分已实现转移转化。先后主持5项国家级科研项目和多项省部级项目。获中国药学会-施维雅药物化学奖（2014年）、中科院卢嘉锡青年人才奖（2015年）、广州市科技进步一等奖1项（团队）和广东省自然科学二等奖1项（团队）。
主要研究方向:
1.新型抗肺癌成药性先导化合物的研究
2.克服临床耐药的新型抗结核药物研究
3.新型激酶类抑制剂的设计研究
代表性论文(近5年)：
1.Xiaoyun Lu,*Jeff B. Smaill, and Ke Ding,* New Promise and Opportunities for Allosteric Kinase Inhibitors. Angew. Chem. Int. Edit.,2020, 10.1002/ange..
2.Jianzhang Yang^#, Marthandam Asokan Shibu^#, Lulu Kong^#, Jinfeng Luo, Farheen BadrealamKhan, Yanhui Huang, Zheng-Chao Tu, Cai-Hong Yun, * Chih-Yang Huang, * Ke Ding,* Xiaoyun Lu. *Design, Synthesis and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as new Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. J. Med. Chem., 2020,63,5,2114-2130.
3.Dongsheng Zhu^#, Huocong Huang^#, Daniel M. Pinkas^#, Jinfeng Luo, Debolina Ganguly, Alice E. Fox, Emily Arner, Qiuping Xiang, Zheng-Chao Tu, Alex N. Bullock,* Rolf A. Brekken,*, Ke Ding,* Xiaoyun Lu*. 2?Amino-2,3-dihydro?1H?indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. Med. Chem. 2019, 62, 7431?7444.
4.Jiayi Shen^#, Tao Zhang^#, Su-Jie Zhu^#, Min Sun, Linjiang Tong, Mengzhen Lai, Rong Zhang, Wei Xu, Ruibo Wu, Jian Ding, Cai-Hong Yun,* Hua Xie,* Xiaoyun Lu,* Ke Ding*, Structure-Based Design of 5?Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). J. Med. Chem.2019, 62, 7302?730
5.Xianglong Hu^#,Baojie Wan ^#,Yang Liu^#,Jiayi Shen,Scott G. Franzblau,Tianyu Zhang,*Ke Ding,* Xiaoyun Lu.*Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents. ACS Med. Chem. Lett., 2019, 10(3), 295–299.
6.Xiaoyun Lu^#*,Zoe Williams^#, Kiel Hards, Jian Tang, Chen-Yi Cheung, Htin Lin Aung, Bangxing Wang, Zhiyong Liu, Xianglong Hu, Anne J. Lenaerts, Lisa Woolhiser, Courtney Hastings, Xiantao Zhang, Zhe Wang, Kyu Y. Rhee, Ke Ding, Tianyu Zhang, and Gregory M Cook* A pyrazolo[1,5-a]pyridine inhibitor of the respiratory cytochrome bcc complex for the treatment of drug-resistant tuberculosis. ACS. Infec. Dise. 2018, 5(2): 239~249.
7.Zhen Wang^#, Yali Zhang^#, Daniel M. Pinkas^#, Alice E. Fox, Jinfeng Luo, Huocong Huang, Shengyang Cui, Qiuping Xiang, Tingting Xu, Qiuju Xun, Dongsheng Zhu, Zhengchao Tu, Xiaomei Ren, Rolf A. Brekken, Alex N. Bullock, Guang Liang*, Ke Ding*, Xiaoyun Lu*.Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. J. Med. Chem.2018, 61:7977-7990.
8.Qiujue Xun^#, Zhang Zhang^#, Jinfeng Luo, Lingjiang Tong, Minghao Huang, zhen Wang, Jian Zou, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu*, Ke Ding*. Design, Synthesis and Structure-Activity Relationship Study of 2-Oxo-3, 4-dihydropyrimido[4, 5-d] Pyrimidines as New Colony Stimulating Factor-1 Receptor (CSF1R) Kinase Inhibitors. J. Med. Chem.2018, 61 (6) :2353-2371.
9.Xiaoyun Lu*, Lei Yu, Zhang Zhang, Xiaomei Ren, Jeff BSmaill, Ke Ding*. Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry. Med. Res. Rev.2018,38:1550–1581.
10.Lei Yu, Minhao Huang, Tianfeng Xu, Linjiang Tong, Xiao-e Yan, Zhang Zhang, Yong Xu, Caihong Yun, Hua Xie*, Ke Ding*, Xiaoyun Lu*. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors ofEGFRL858R/T790M mutant with improved pharmacokinetic properties.Eur.J. Med. Chem.2017,126, 1107-1117.
电话：
联系方式:E-mail:luxy2016@jnu.edu.cn